Opher Gileadi obtained his B.Sc. in Biology (1983) and PhD in Biochemistry at the Hebrew University (1989) and was then a postdoctoral fellow at Stanford University Medical School. Subsequently he led a research group at the Weizmann Institute of Science. Since 2004 he has been at the Structural Genomics Consortium (SGC) at the University of Oxford, first as head of the Bioytechnology group, then as Principal Investigator of the Genome Integrity & Repair Group. Opher studied the biochemical basis of gene expression and DNA repair using a variety of approaches, including the analysis of differential mRNA in human trophoblast cells, transcription factors studies using purified systems and genetics of yeast, and only analyzes molecule of protein: DNA interactions. The SGC (Structural Genomics Consortium), Opher established the group of biotechnology, developing high-yield production methods (high-throughput) of human proteins for crystallization. He now leads the Genome Integrity Group, which studies proteins and DNA repair proteins associated with human genetic disease. Recent work includes helicases structures RecQ DNA endonucleases and DNA repair cross-link and biochemical characterization of mutant genes congenital syndrome Carpenter and Dyserythropoietic congenital anemia. It is currently also developing methods to intervene in DNA repair using small molecules, such as new inhibitors of the Bloom DNA helicase. In July 2015, Opher has relocated to Brazil to head the SGC Kinase Chemical Biology Center at the State University of Campinas (UNICAMP).
(Source: Lattes Curriculum)